Last reviewed · How we verify
Placebo-cyclophosphamide
Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death.
Cyclophosphamide is an alkylating agent that interferes with DNA replication, causing cell death. Used for Treatment of various types of cancer, including lymphomas and leukemias.
At a glance
| Generic name | Placebo-cyclophosphamide |
|---|---|
| Also known as | Nacl |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Alkylating agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, which prevents them from replicating and ultimately leads to cell death. This mechanism is particularly effective against rapidly dividing cells, such as those found in tumors.
Approved indications
- Treatment of various types of cancer, including lymphomas and leukemias
Common side effects
- Myelosuppression
- Nausea and vomiting
- Hair loss
- Infection
- Bleeding
Key clinical trials
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (PHASE2)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (PHASE3)
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer (PHASE3)
- Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid (PHASE3)
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |